CLS Therapeutics Inc., a preclinical-stage biopharmaceutical company developing next-generation gene therapy anticancer drugs, today announced that George Tetz, MD, Ph.D., Chief Executive Officer, presented the poster, “TRANSFORMATIVE ANTICANCER GENE THERAPY PLATFORM ADDRESSING A NOVEL THERAPEUTIC TARGET” at the Cancer Metabolism and Signaling organized by the New York Academy of Sciences May 9, 2019, in New York, New York.
Dr. Tetz’s presentation provided an overview of CLS-014, an engineered gene therapy platform addressing unmet need in pancreatic cancer with multiple follow-up extension opportunities. CLS-014 is an AAV-based vector that targets cell-free DNA, and has the potential for the treatment of solid tumors. The poster presentation also provided an overview of in vivo animal efficacy evaluating CLS-014 for the treatment of pancreatic cancer.
Poster Session Presentation Details:
- Title: Transformative Anticancer Gene Therapy Platform Addressing A Novel Therapeutic Target
- Poster Number: 31
- Event: Cancer Metabolism and Signaling (NYAS)
- Date: Thursday, May 9, 2019
- Event Website: https://www.nyas.org/events/2019/cancer-metabolism-and-signaling/
About the CLS Therapeutics:
CLS Translating the new biology of cell-free DNA into novel therapeutic approaches for multiple cancers, beginning with our first program for pancreatic cancer. PC is the third-leading cause of cancer deaths in the United State with over 45,000 dying in 2018. It is expected to become the leading cause of cancer mortality already by 2030. 1-year survival is less than 30%. 5-year survival is less than 8%.
CLS-014 is in silico designed AAV-based vector encoding hyperactive human DNase I transgene cassette. Intravenous injection of the vector with a liver specific promoter leads to long term increase of serum DNase I activity that cleaves cell-free DNA in the blood and therefore affecting primary tumor growth, metastasis and complications associated with NETosis.
CLS-014 is administered as a single injection with any first-line chemotherapeutic agents.
CLS-Therapeutics presented animal data demonstrating the efficacy of CLS-014 in the treatment of orthotopic pancreatic mouse xenograft model. CLS-014 alone, inhibited primary tumor growth and metastasis and potentiates nab-paclitaxel.
About CLS Therapeutics Inc.
CLS-Therapeutics Inc. is a preclinical-stage biopharmaceutical company focused to deliver on the promise of circulating nucleic acid science to advance a new generation of transformative gene therapies for cancer patients.
NEW YORK, NY / September 22, 2022 / CLS Therapeutics, cancer gene therapy company utilizing a novel therapeutic target, announces that its project been selected as one of the semi-finalists of “Creating the World·Sailing to the Future” Innovation and Entrepreneurship Competition 2022 Hangzhou.
NEW YORK, NY / April 08, 2020 / CLS Therapeutics, a privately held anticancer gene therapy platform company addressing a novel therapeutic target, announces presentation at the upcoming 2020 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting that will be held from April 29 to May 2, 2019 that is planned to be held May 12 – May 15, 2020, at the Hynes Convention Center in Boston, USA.
Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic”), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced the signing of a patent assignment from CLS Therapeutics, Inc. (“CLS”) to Xenetic related to Xenetic’s previously announced collaboration with VolitionRx Limited (NYSE AMERICAN:VNRX) (“Volition”), a multi-national epigenetics company, and CLS, a biopharmaceutical company developing first-in-class therapies based on the discovery of novel therapeutic targets. In consideration of the patent assignment, Xenetic will also issue 850,000 shares of common stock to CLS.